Pre-diagnosis observational and prescription history associated with Alzheimers disease incidence
Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes
Moreover, for people already dealing with substance abuse, it decreased adverse events and the risk of death by 50%.[ref] Phamacogenomics and GLP-1 RAs: Theres an individual variability in treatment response to most medications, including GLP-1 RAs
Protein requirements beyond the RDA: implications for optimizing health
It includes FDA-approved tablets like Rybelsus, compounded sublingual drops from pharmacies, and even newer formulations hitting the market
Lingvay I, Sumithran P, Cohen RV, le Roux CW (2022) Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation